<DOC>
	<DOCNO>NCT02387372</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics lung penetration intravenous Ceftolozane/tazobactam critically ill participant .</brief_summary>
	<brief_title>Plasma Pharmacokinetics ( PK ) &amp; Lung Penetration Ceftolozane/Tazobactam Participants With Pneumonia ( MK-7625A-007 )</brief_title>
	<detailed_description>This Phase 1 , prospective , multicenter , non-comparative , open-label study characterize plasma pharmacokinetics intrapulmonary penetration ceftolozane/tazobactam two group participant . Group 1 : approximately 25 ventilate participant suspect proven pneumonia receive concurrent standard antibiotic therapy . Within Group 1 , effort make enroll approximately 5 participant CLCR ≥ 150 mL/min ( calculate Cockcroft-Gault equation ) . Group 2 : 8-10 critically ill participant CLCR ≥180 mL/min ( calculate Cockcroft-Gault equation ) .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<mesh_term>Ceftolozane , tazobactam drug combination</mesh_term>
	<criteria>1 . Provide write informed consent prior studyrelated procedure part normal medical care . 2 . If female , must pregnant nursing , either : 1 . Not childbearing potential , defined postmenopausal least 1 year surgically sterile due bilateral tubal ligation , bilateral oophorectomy , hysterectomy ; 2 . Of childbearing potential : Is practice effective method contraception ( e.g. , oral/parenteral contraceptive barrier method ) least 1 month prior baseline assessment , Has vasectomize partner , Is currently abstinent sexual intercourse . Participants must willing practice choose contraceptive method remain abstinent conduct study least 30 day last dose study medication . 3 . Nonvasectomized male require practice effective birth control method ( e.g. , abstinence , use condom use barrier device ) conduct study least 30 day last dose study medication ; 4 . Participants Group 1 must meet following criterion : 1 . Males females age 18 year old ; 2 . Intubated mechanical ventilation least 24 hour prior time enrollment ( include participant tracheostomy mechanically ventilate ) ; 3 . Proven suspect bacterial pneumonia , confirm presence least one prescribed clinical sign symptom . 4 . Receiving antibiotic therapy proven suspect bacterial pneumonia time enrollment expect continue antibiotic therapy study 5 . Participants Group 2 must meet following criterion : 1 . Males female age 18 54 year ; 2 . Acute Physiology Chronic Health Evaluation II ( APACHE II ) score 12 35 , inclusive ; 3 . CLCR ≥180 mL/min ( calculate CockcroftGault equation use actual body weight ) within 24 hour dose ; 4 . Documented infection presume infection . 1 . Has document history moderate severe hypersensitivity allergic reaction βlactam antibacterial ( history mild rash follow uneventful reexposure contraindication enrollment ) ; 2 . Hemoglobin &lt; 7 g/dL baseline ; 3 . Prior ( within 24 hour first dose study drug ) concomitant receipt piperacillin/tazobactam , probenecid ceftolozane/tazobactam ( nonstudy use ) ; 4 . Any rapidlyprogressing disease immediately lifethreatening illness ( defined imminent death within 48 hour opinion Investigator ) ; 5 . Any condition circumstance , opinion Investigator , would compromise safety participant quality study data ; 6 . Planned prior participation interventional drug study within last 30 day ; 7 . Participants Group 1 must meet following criterion : 1 . Receipt effective systemic antibiotic therapy treatment proven suspect bacterial pneumonia 72 hour prior start first dose study drug 2 . Any following diagnosis condition may interfere PK assessment/interpretation : Cystic fibrosis , acute exacerbation chronic bronchitis obstructive airway disease , chronic severe respiratory disease , active pulmonary tuberculosis , Full thickness burn ( great 15 % total body surface area ) , Lung transplant recipient donor , Any condition situation bronchoscopy advisable ; 8 . Endstage renal disease define CLCR &lt; 15 mL/min ( calculate CockcroftGault equation use actual body weight ) , OR requirement continuous renal replacement therapy hemodialysis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>